CLINICAL AND IMMUNOLOGICAL RATIONALE FOR COMPLEX TREATMENT OF CHRONIC GENERALIZED PERIODONTITIS IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE
Keywords:
Aim. To substantiate, from clinical and immunological standpoints, a complex approach to the treatment of chronic generalized periodontitis in patients with metabolic fatty liver disease.Abstract
Relevance. Chronic periodontitis affects about half of adults worldwide [1], and fatty liver disease has an estimated global prevalence of about 24% [2]. Both are chronic inflammatory conditions that frequently coexist in the setting of metabolic syndrome. In 2023 a multisociety consensus replaced the term NAFLD with metabolic dysfunction-associated steatotic liver disease (MASLD), which requires hepatic steatosis plus at least one of five cardiometabolic risk factors [3]. Because periodontitis is a modifiable factor and its treatment may improve liver parameters [4], a clinical and immunological rationale for a combined approach is needed.
References
1.Lyu Z., Zhu J., Chen D. Chronic periodontitis and non-alcoholic fatty liver disease: recent advances in mechanisms of association. Int J Gen Med. 2025;18:7357–7369. doi:10.2147/IJGM.S554833.
2. Younossi Z., Anstee Q.M., Marietti M., et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20.
3. Rinella M.E., Lazarus J.V., Ratziu V., et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542–1556. doi:10.1016/j.jhep.2023.06.003.
4. Kamata Y., Kessoku T., Shimizu T., et al. Periodontal treatment and usual care for nonalcoholic fatty liver disease: a multicenter, randomized controlled trial. Clin Transl Gastroenterol. 2022;13(11):e00520. doi:10.14309/ctg.0000000000000520.
5. Wijarnpreecha K., Panjawatanan P., Cheungpasitporn W., et al. The association between periodontitis and nonalcoholic fatty liver disease: a systematic review and meta-analysis. J Gastrointestin Liver Dis. 2020;29(2):211–217. doi:10.15403/jgld-841.
6. Iwasaki T., Hirose A., Azuma T., et al. Correlation between ultrasound-diagnosed non-alcoholic fatty liver and periodontal condition in a cross-sectional study in Japan. Sci Rep. 2018;8:7496.
7. Weintraub J.A., Lopez Mitnik G., Dye B.A. Oral diseases associated with nonalcoholic fatty liver disease in the United States. J Dent Res. 2019;98(11):1219–1226.
8. Alazawi W., Bernabe E., Tai D., et al. Periodontitis is associated with significant hepatic fibrosis in patients with non-alcoholic fatty liver disease. PLoS One. 2017;12(12):e0185902.
9. Ding L.Y., Liang L.Z., Zhao Y.X., et al. Porphyromonas gingivalis-derived lipopolysaccharide causes excessive hepatic lipid accumulation via activating NF-κB and JNK signaling pathways. Oral Dis. 2019;25:1789–1797.
10. Nakajima M., Arimatsu K., Kato T., et al. Oral administration of P. gingivalis induces dysbiosis of gut microbiota and impaired barrier function leading to dissemination of enterobacteria to the liver. PLoS One. 2015;10(7):e0134234.
11. Paraskevas S., Huizinga J.D., Loos B.G. A systematic review and meta-analyses on C-reactive protein in relation to periodontitis. J Clin Periodontol. 2008;35(4):277–290.
12. Suárez L.J., Vargas D.E., Rodríguez A., et al. Systemic Th17 response in the presence of periodontal inflammation. J Appl Oral Sci. 2020;28:e20190490.